Have you or your loved ones been diagnosed with central nervous system lymphoma?

You may be eligible to participate in a central nervous system lymphoma clinical trial.

Have you or your loved ones been diagnosed with central nervous system lymphoma? You may be eligible to participate in a central nervous system lymphoma clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Lymphoma
NCT02420795 | Phase 1 phase 2 | Interventional

Have you or your loved ones been diagnosed with central nervous system lymphoma?

You may be eligible to participate in a central nervous system lymphoma clinical trial.

Have you or your loved ones been diagnosed with central nervous system lymphoma? You may be eligible to participate in a central nervous system lymphoma clinical trial.

Terminated

Male & Female

18 Years +

This study has recruited 16 Participants

This phase I/II trial studies the side effects and the best dose of v-akt murine thymoma viral oncogene homolog (Akt)/mitogen-activated protein kinase 1(ERK) inhibitor ONC201 and to see how well it works in treating patients with non-Hodgkin's lymphoma that has returned after a period of improvement or does not respond to treatment. Akt/ERK inhibitor ONC201 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.